Kamran Alam
2023 - Taysha Gene Therapies
In 2023, Kamran Alam earned a total compensation of $975.4K as Chief Financial Officer at Taysha Gene Therapies, a 19% decrease compared to previous year.
Compensation breakdown
| Non-Equity Incentive Plan | $148,950 |
|---|---|
| Option Awards | $402,039 |
| Salary | $413,751 |
| Other | $10,661 |
| Total | $975,401 |
Alam received $413.8K in salary, accounting for 42% of the total pay in 2023.
Alam also received $149K in non-equity incentive plan, $402K in option awards and $10.7K in other compensation.
Rankings
In 2023, Kamran Alam's compensation ranked 1,246th out of 3,006 executives tracked by ExecPay. In other words, Alam earned more than 58.5% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 1,246 out of 3,006 | 59th |
Division Manufacturing | 738 out of 1,650 | 55th |
Major group Chemicals And Allied Products | 494 out of 918 | 46th |
Industry group Drugs | 482 out of 881 | 45th |
Industry Biological Products, Except Diagnostic Substances | 139 out of 213 | 35th |
Source: SEC filing on April 18, 2024.
Alam's colleagues
We found two more compensation records of executives who worked with Kamran Alam at Taysha Gene Therapies in 2023.
News
Taysha Gene Therapies CEO Sean Nolan's 2023 pay slips 20% to $1.5M
April 18, 2024
Taysha Gene Therapies CEO RA Session's 2022 pay falls 57% to $2M
May 8, 2023
Taysha Gene Therapies CEO RA Session's 2021 pay slips 3% to $4.6M
April 28, 2022
Inotek Pharmaceuticals CEO Gaurav Shah's 2019 pay falls 39% to $3.9M
April 24, 2020
Aquinox Pharmaceuticals CEO Jonathan Drachman receives $3.8M in 2019
March 24, 2020
Aquinox Pharmaceuticals CEO David Main's 2018 pay jumps 39% to $4.2M
October 2, 2019